This company listing is no longer active
LYS Stock Overview
Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Lysogene S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.28 |
| 52 Week High | €0.82 |
| 52 Week Low | €0.23 |
| Beta | 0.91 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -59.49% |
| 33 Year Change | -88.45% |
| 5 Year Change | -86.16% |
| Change since IPO | -95.90% |
Recent News & Updates
Shareholder Returns
| LYS | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 0% | -4.8% | -2.1% |
| 1Y | -59.5% | -24.7% | -0.7% |
Return vs Industry: LYS underperformed the French Biotechs industry which returned -21.8% over the past year.
Return vs Market: LYS underperformed the French Market which returned 17.5% over the past year.
Price Volatility
| LYS volatility | |
|---|---|
| LYS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.4% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: LYS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine LYS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 22 | Karen Pignet-Aiach | www.lysogene.com |
Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a research collaboration with the Yeda Research and Development Co Ltd.
Lysogene S.A. Fundamentals Summary
| LYS fundamental statistics | |
|---|---|
| Market cap | €4.95m |
| Earnings (TTM) | -€7.37m |
| Revenue (TTM) | €12.77m |
0.4x
P/S Ratio-0.7x
P/E RatioIs LYS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LYS income statement (TTM) | |
|---|---|
| Revenue | €12.77m |
| Cost of Revenue | €0 |
| Gross Profit | €12.77m |
| Other Expenses | €20.14m |
| Earnings | -€7.37m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 100.00% |
| Net Profit Margin | -57.76% |
| Debt/Equity Ratio | -402.9% |
How did LYS perform over the long term?
See historical performance and comparison